// App-Quantinova.ai

2565 : Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.

Researchers

Presenter

  • Steven Lacy

Principal Investigators

  • Matthew M Hutmacher

  • Bei Yang

  • Robert J. Motzer

  • Bernard J. Escudier

  • Thomas Powles

  • Toni K. Choueiri

  • Dale Miles

  • Jace Nielsen

Medical Centers

  • Exelixis, Inc, South San Francisco, CA

  • Ann Arbor Pharmacometrics Group, Ann Arbor, MI

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Institut Gustave-Roussy, Villejuif, France

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • III

Study Id's

  • NCT02496208

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved